Lauren Bowen
General Practice · Phoenix, AZNPI 1356781843
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $101,807 of the $126,861 with a category attached, or 80.3%. AbbVie accounts for 91.7% of it on its own, with 59 other manufacturers making up the rest. 2025 is the largest year on record at $62,100, more than ten times the $1,847 reported in 2019. Among general practice clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,591 payments — averaging $79.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$116K
- Amgen$1K
- Upsher-smith Laboratories LLC$1K
- Pfizer$919
- Lundbeck LLC$548
- Tonix Medicines, Inc.$498
- plus $6K from 54 others
What the payments were for
- Speaking & faculty fees$101,80780%
- Travel & lodging$6,5235%
- Food & beverage$18,51415%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$126,861 in reported general payments places this provider in the 95th percentile of 1,998 general practice providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 87 | $69,120 |
| VyeptiEptinezumab-Jjmr | 14 | $51,359 |
| Emgality PenGalcanezumab-Gnlm | 37 | $33,779 |
| Nurtec OdtRimegepant Sulfate | 12 | $21,944 |
| QuliptaAtogepant | 14 | $21,844 |
| Sumatriptan Succinate | 133 | $10,829 |
| ReyvowLasmiditan Succinate | 14 | $10,245 |
| Eletriptan HbrEletriptan Hydrobromide | 26 | $3,550 |
| RizatriptanRizatriptan Benzoate | 128 | $2,633 |
| Sumatriptan | 11 | $2,077 |
| Carbamazepine ErCarbamazepine | 16 | $1,513 |
| Oxcarbazepine | 26 | $1,399 |
| Naratriptan Hcl | 35 | $925 |
| Gabapentin | 37 | $859 |
| Topiramate | 58 | $833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lundbeck LLCVyepti | $548 | $51,35914 claims |
| PfizerNurtec Odt | $919 | $21,94412 claims |
| AbbVieQulipta | $116,391 | $21,84414 claims |
| Lilly USA, LLCReyvow | $456 | $10,24514 claims |
| Upsher-smith Laboratories LLCTopiramate | $1,202 | $83358 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,998 general practice providers in Arizona.
Other general practice in Phoenix
- Curtis HamannPhoenix$1.9M
- Mehrdad MehranfarPhoenix$967K
- Brian HarrisPhoenix$37K
- Peter SpilotroPhoenix$14K
- Tyler ClaytonPhoenix$12K
- Rahul KodePhoenix$11K
- Tuan lePhoenix$9K
- Matthew LonierPhoenix$9K
- Shawn BensoPhoenix$9K
- Kathleen MillerPhoenix$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.